181 related articles for article (PubMed ID: 35925680)
1. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function.
Wang J; Wang Q; Guan Y; Sun Y; Wang X; Lively K; Wang Y; Luo M; Kim JA; Murphy EA; Yao Y; Cai G; Fan D
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 35925680
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
3. Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
Sharma S; Opyrchal M; Lu X
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 36189796
[TBL] [Abstract][Full Text] [Related]
4. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
[TBL] [Abstract][Full Text] [Related]
5. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
6. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
7. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
8. Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Hong BS; Ryu HS; Kim N; Kim J; Lee E; Moon H; Kim KH; Jin MS; Kwon NH; Kim S; Kim D; Chung DH; Jeong K; Kim K; Kim KY; Lee HB; Han W; Yun J; Kim JI; Noh DY; Moon HG
Cancer Res; 2019 Apr; 79(7):1520-1534. PubMed ID: 30737233
[TBL] [Abstract][Full Text] [Related]
9. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
10. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.
Hu Y; Zhu Q; Tang L
PLoS One; 2014; 9(3):e92099. PubMed ID: 24637915
[TBL] [Abstract][Full Text] [Related]
11. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/β-catenin signaling.
Jiang J; Yang X; He X; Ma W; Wang J; Zhou Q; Li M; Yu S
Chem Biol Interact; 2019 Apr; 302():74-82. PubMed ID: 30738779
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer.
Hodge J; Wang F; Wang J; Liu Q; Saaoud F; Wang Y; Singh UP; Chen H; Luo M; Ai W; Fan D
Oncoimmunology; 2020; 9(1):1724761. PubMed ID: 32117588
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers.
Ekiz HA; Huffaker TB; Grossmann AH; Stephens WZ; Williams MA; Round JL; O'Connell RM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30721153
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
Zhao X; Yuan C; Wangmo D; Subramanian S
Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
[TBL] [Abstract][Full Text] [Related]
18. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA VCAN-AS1 promotes the malignant behaviors of breast cancer by regulating the miR-106a-5p-mediated STAT3/HIF-1α pathway.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Bioengineered; 2021 Dec; 12(1):5028-5044. PubMed ID: 34365889
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
